Why the study?
Does enoxaparin prevent venous thromboembolism safely in general surgery patients?
Does enoxaparin prevent venous thromboembolism safely in general surgery patients?
Real-world enoxaparin prophylaxis in general surgery patients is associated with low rates of VTE but carries a 5.4% risk of major bleeding, particularly in patients with kidney disease or concurrent NSAID use.
Answers are grounded in this paper and cite their sources.
Bleeding risk with enoxaparin prophylaxis warrants caution in kidney disease or NSAID users; leaves open optimal VTE prevention strategies in general surgery.
BACKGROUND: We aimed to document enoxaparin use in real world and identify the risk factors for bleeding complications. METHODS: Postauthorization study in 448 surgical patients receiving enoxaparin prophylaxis. Complete compression ultrasound (CCUS) was performed at day 10 ± 3. RESULTS: During treatment, 11 of 448 patients had suspected deep venous thrombosis (DVT) but none confirmed. One patient had symptoms of pulmonary embolism ([PE] 0.22%; 95% confidence interval [CI] -0.21-0.66). There were no asymptomatic cases detected upon CCUS. At the 90-day follow-up, 4 (0.9%) of the 440 patients had DVT symptoms (95% CI 0.02-1.80) and none had PE; 5.4% had major and 11.6% any type of bleeding complications. Major bleeding was more frequent in those with kidney disease (odds ratio [OR] 5.53), those who are bedridden (OR 5.49), those with peridural indwelling catheters (OR 4.01), and those on nonsteroidal anti-inflammatory drugs (OR 3.33). CONCLUSIONS: Enoxaparin is effective and safe in surgical patients to prevent venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Schellong et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: